Pill-Based HER2 Blocker Matches Standard Antibody Duo in Early Breast Cancer Trial
A multicenter phase II trial found that a pyrotinib-based neoadjuvant regimen achieved pathological response rates comparable to the standard trastuzumab-pertuzumab ...
